Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:CLLS NASDAQ:FBRX NASDAQ:NRXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.57-0.9%$1.49$1.18▼$2.70$413.85M1.931.72 million shs267,247 shsCLLSCellectis$4.06+1.9%$3.68$1.33▼$5.48$408.89M2.9441,115 shs1,467 shsFBRXForte Biosciences$25.17-3.2%$28.07$6.35▼$35.80$349.61M3.01263,735 shs33,281 shsNRXPNRx Pharmaceuticals$2.77-2.0%$2.33$1.62▼$3.84$91.76M2.021.05 million shs217,042 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+0.64%+7.48%+6.04%+10.49%+19.70%CLLSCellectis+3.38%+0.76%+10.86%+2.31%+148.75%FBRXForte Biosciences+8.24%-7.77%-25.90%-11.80%+307.52%NRXPNRx Pharmaceuticals-8.44%-8.74%+27.03%+50.00%+38.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.57-0.9%$1.49$1.18▼$2.70$413.85M1.931.72 million shs267,247 shsCLLSCellectis$4.06+1.9%$3.68$1.33▼$5.48$408.89M2.9441,115 shs1,467 shsFBRXForte Biosciences$25.17-3.2%$28.07$6.35▼$35.80$349.61M3.01263,735 shs33,281 shsNRXPNRx Pharmaceuticals$2.77-2.0%$2.33$1.62▼$3.84$91.76M2.021.05 million shs217,042 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+0.64%+7.48%+6.04%+10.49%+19.70%CLLSCellectis+3.38%+0.76%+10.86%+2.31%+148.75%FBRXForte Biosciences+8.24%-7.77%-25.90%-11.80%+307.52%NRXPNRx Pharmaceuticals-8.44%-8.74%+27.03%+50.00%+38.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 2.89Moderate Buy$8.50443.13% UpsideCLLSCellectis 2.83Moderate Buy$6.7566.42% UpsideFBRXForte Biosciences 2.50Moderate Buy$67.00166.20% UpsideNRXPNRx Pharmaceuticals 2.50Moderate Buy$38.251,283.36% UpsideCurrent Analyst Ratings BreakdownLatest NRXP, CLLS, FBRX, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026NRXPNRx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.004/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026NRXPNRx Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $49.004/27/2026NRXPNRx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.004/20/2026CLLSCellectis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AUTLAutolus Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/20/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.004/14/2026CLLSCellectis Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$8.004/9/2026AUTLAutolus Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/31/2026AUTLAutolus Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$12.00 ➝ $10.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$75.39M5.52N/AN/A$0.67 per share2.34CLLSCellectis$79.59M5.11N/AN/A$0.76 per share5.34FBRXForte BiosciencesN/AN/AN/AN/A$4.71 per shareN/ANRXPNRx Pharmaceuticals$1.23M74.64N/AN/A($0.54) per share-5.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$287.53M-$1.08N/AN/AN/A-381.40%-99.05%-42.31%5/14/2026 (Estimated)CLLSCellectis-$67.59M-$0.67N/AN/AN/A-84.92%-69.38%-19.51%7/30/2026 (Estimated)FBRXForte Biosciences-$69.38M-$4.77N/AN/AN/AN/A-98.36%-82.81%5/21/2026 (Estimated)NRXPNRx Pharmaceuticals-$28.62M-$1.39N/A2.25N/AN/AN/A-265.03%5/21/2026 (Estimated)Latest NRXP, CLLS, FBRX, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026FBRXForte Biosciences-$1.16N/AN/AN/AN/AN/A5/21/2026Q1 2026NRXPNRx Pharmaceuticals-$0.01N/AN/AN/A$25.57 millionN/A5/14/2026Q1 2026AUTLAutolus Therapeutics-$0.29N/AN/AN/A$26.27 millionN/A5/11/2026Q1 2026CLLSCellectis-$0.2583-$0.18+$0.0783-$0.18$11.04 millionN/A5/11/2026Q1 2026FBRXForte BiosciencesN/A-$1.24N/A-$1.24N/AN/A3/31/2026Q4 2025FBRXForte Biosciences-$1.42-$1.45-$0.03-$1.45N/AN/A3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 million3/23/2026Q4 2025NRXPNRx Pharmaceuticals-$0.09$0.19+$0.28$0.19$7.53 million$0.98 million3/19/2026Q4 2025CLLSCellectis-$0.10-$0.26-$0.16-$0.26$10.74 million$15.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A5.945.48CLLSCellectis0.981.621.62FBRXForte BiosciencesN/A3.883.88NRXPNRx PharmaceuticalsN/A0.310.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%CLLSCellectis63.90%FBRXForte Biosciences77.63%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%CLLSCellectis16.41%FBRXForte Biosciences4.40%NRXPNRx Pharmaceuticals6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCLLSCellectis290100.34 million83.87 millionOptionableFBRXForte Biosciences513.89 million13.28 millionOptionableNRXPNRx Pharmaceuticals233.07 million30.95 millionOptionableNRXP, CLLS, FBRX, and AUTL HeadlinesRecent News About These CompaniesNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in ...May 7, 2026 | markets.businessinsider.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and SuicidalityMay 7, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of "Moderate Buy" by BrokeragesMay 7, 2026 | marketbeat.comWhy NRx Pharmaceuticals, Inc.’s (NRXP) Stock Is Up 6.67%May 5, 2026 | aaii.comAD. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)May 5, 2026 | marketbeat.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free KetamineMay 5, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Large Growth in Short InterestApril 29, 2026 | marketbeat.comEquities Analysts Offer Predictions for NRXP Q1 EarningsApril 28, 2026 | marketbeat.comNRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $49.00 at Ascendiant Capital MarketsApril 27, 2026 | marketbeat.comNRx Pharmaceuticals (NASDAQ:NRXP) Earns "Buy" Rating from HC WainwrightApril 27, 2026 | marketbeat.comNRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine ProgramApril 22, 2026 | globenewswire.comNRx Pharmaceuticals (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug DevelopmentApril 20, 2026 | theglobeandmail.comNRx Pharmaceuticals' (NRXP) Buy Rating Reiterated at D. Boral CapitalApril 20, 2026 | marketbeat.comNRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and SuicidalityApril 20, 2026 | globenewswire.comNRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with ...April 15, 2026 | caledonianrecord.comCNRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder ApplicationsApril 15, 2026 | globenewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial OfficerApril 13, 2026 | markets.businessinsider.comNRx Pharmaceuticals Appoints Glenn Tyson as Chief Commercial Officer Ahead of Anticipated Drug ApprovalsApril 13, 2026 | quiverquant.comQNRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial OfficerApril 13, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 12, 2026 | marketbeat.comNRx Pharmaceuticals Receives Preliminary Labeling Alignment from FDA for Preservative-Free Ketamine ProductApril 6, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRXP, CLLS, FBRX, and AUTL Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.56 -0.02 (-0.95%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Cellectis NASDAQ:CLLS$4.06 +0.08 (+1.91%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Forte Biosciences NASDAQ:FBRX$25.17 -0.83 (-3.20%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.NRx Pharmaceuticals NASDAQ:NRXP$2.76 -0.06 (-1.95%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
